PE20090887A1 - DERIVADOS DE 1H-PIRAZOL-[3,4-d]-PIRIMIDINA, 9H-PURINA Y 7H-PIRROL-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASA P70 S6 - Google Patents

DERIVADOS DE 1H-PIRAZOL-[3,4-d]-PIRIMIDINA, 9H-PURINA Y 7H-PIRROL-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASA P70 S6

Info

Publication number
PE20090887A1
PE20090887A1 PE2008000756A PE2008000756A PE20090887A1 PE 20090887 A1 PE20090887 A1 PE 20090887A1 PE 2008000756 A PE2008000756 A PE 2008000756A PE 2008000756 A PE2008000756 A PE 2008000756A PE 20090887 A1 PE20090887 A1 PE 20090887A1
Authority
PE
Peru
Prior art keywords
pyrimidine
imidazol
piperidin
phenyl
pyrrol
Prior art date
Application number
PE2008000756A
Other languages
English (en)
Spanish (es)
Inventor
Robert Dean Dally
Jianping Huang
Sajan Joseph
Timothy Alan Shepherd
Christian L Holst
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20090887A1 publication Critical patent/PE20090887A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2008000756A 2007-05-11 2008-04-29 DERIVADOS DE 1H-PIRAZOL-[3,4-d]-PIRIMIDINA, 9H-PURINA Y 7H-PIRROL-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASA P70 S6 PE20090887A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91733107P 2007-05-11 2007-05-11

Publications (1)

Publication Number Publication Date
PE20090887A1 true PE20090887A1 (es) 2009-07-13

Family

ID=39765082

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000756A PE20090887A1 (es) 2007-05-11 2008-04-29 DERIVADOS DE 1H-PIRAZOL-[3,4-d]-PIRIMIDINA, 9H-PURINA Y 7H-PIRROL-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASA P70 S6

Country Status (33)

Country Link
US (2) US8093383B2 (enExample)
EP (1) EP2148880B1 (enExample)
JP (1) JP5503532B2 (enExample)
KR (1) KR101088219B1 (enExample)
CN (1) CN101679439B (enExample)
AR (1) AR066344A1 (enExample)
AU (1) AU2008251692B2 (enExample)
BR (1) BRPI0811212A2 (enExample)
CA (1) CA2687265C (enExample)
CL (1) CL2008001230A1 (enExample)
CO (1) CO6241109A2 (enExample)
CR (1) CR11106A (enExample)
DK (1) DK2148880T3 (enExample)
DO (1) DOP2009000257A (enExample)
EA (1) EA016445B1 (enExample)
EC (1) ECSP099721A (enExample)
ES (1) ES2483726T3 (enExample)
GT (1) GT200900292A (enExample)
HR (1) HRP20140611T1 (enExample)
IL (1) IL201564A (enExample)
MA (1) MA31433B1 (enExample)
MX (1) MX2009012075A (enExample)
MY (1) MY154898A (enExample)
NZ (1) NZ580423A (enExample)
PE (1) PE20090887A1 (enExample)
PL (1) PL2148880T3 (enExample)
PT (1) PT2148880E (enExample)
RS (1) RS53451B (enExample)
SI (1) SI2148880T1 (enExample)
TN (1) TN2009000446A1 (enExample)
TW (1) TWI423805B (enExample)
UA (1) UA99284C2 (enExample)
WO (1) WO2008140947A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
WO2010019762A1 (en) * 2008-08-13 2010-02-18 Jenrin Discovery Purine compounds as cannabinoid receptor blockers
BRPI0921888A2 (pt) 2008-11-11 2015-12-29 Lilly Co Eli terapia de combinação de inibidor de egfr inibidor da p70 s6 quinase
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
CA2743242A1 (en) * 2008-11-11 2010-05-20 Eli Lilly And Company P70 s6 kinase inhibitor and mtor inhibitor combination therapy
KR101699991B1 (ko) 2009-02-11 2017-01-26 메르크 파텐트 게엠베하 신규의 아미노 아자헤테로시클릭 카르복사미드
ES2654332T3 (es) 2009-08-07 2018-02-13 Merck Patent Gmbh Nuevos compuestos azaheterocíclicos
BR112012011328A2 (pt) * 2009-10-23 2016-11-22 Lilly Co Eli inibidores de akt
BR112012019459A2 (pt) 2010-02-03 2017-10-17 Signal Pharm Llc identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase.
US9586938B2 (en) 2010-07-29 2017-03-07 Merck Patent Gmbh Cyclic amine azaheterocyclic carboxamides
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
EA023821B1 (ru) 2010-11-24 2016-07-29 Мерк Патент Гмбх Хиназолинкарбоксамидазетидины, их применение в лечении гиперпролиферативных заболеваний и содержащие их композиции
HRP20171554T1 (hr) * 2011-09-12 2017-11-17 Merck Patent Gmbh Novi imidazol amini kao modulatori aktivnosti kinaze
ES2646759T3 (es) 2011-09-12 2017-12-15 Merck Patent Gmbh Derivados de aminopirimidina para uso como moduladores de la actividad de la quinasa
JP6318156B2 (ja) * 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドPlexxikon Inc. キナーゼをモジュレートするための化合物および方法、ならびにその指標
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
AR093511A1 (es) 2012-11-16 2015-06-10 Merck Patent Gmbh Derivados de imidazol-piperidinilo como moduladores de la actividad de cinasas
AR093512A1 (es) 2012-11-16 2015-06-10 Merck Patent Gmbh Derivados heterociclicos como moduladores de la actividad de cinasas
EA033655B1 (ru) 2012-11-29 2019-11-13 Merck Patent Gmbh Производные азахиназолин карбоксамида
MX370448B (es) 2013-03-11 2019-12-13 Merck Patent Gmbh Derivados de 6- [4- (1h-imidazol-2-il) piperidin-1-il] pirimidin-4-amina como moduladores de la actividad de cinasa.
WO2014172425A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
HK1221168A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
CA2908742C (en) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
MY189663A (en) 2013-04-17 2022-02-23 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ,エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
EP3549940A1 (en) 2013-04-17 2019-10-09 Signal Pharmaceuticals, LLC Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
CN107474051B (zh) 2013-05-29 2020-10-30 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
NZ725361A (en) 2014-04-03 2022-09-30 Merck Patent Gmbh Combinations of cancer therapeutics
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
WO2016040078A1 (en) * 2014-09-10 2016-03-17 Eli Lilly And Company Substituted phenyl imidazolyl piperidyl compounds as p70s6k1 inhibitors
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN106187899B (zh) * 2016-06-28 2019-07-16 绍兴文理学院 一种氟代氮杂芳烃的合成方法
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
IL302951A (en) 2020-11-16 2023-07-01 Merck Patent Gmbh Kinase inhibitor combinations for cancer treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
WO2005117909A2 (en) * 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
AU2005322085B2 (en) 2004-12-28 2012-07-19 Exelixis, Inc. [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
CO6241109A2 (es) 2011-01-20
WO2008140947A1 (en) 2008-11-20
CA2687265C (en) 2012-12-04
HRP20140611T1 (hr) 2014-08-15
US20090163714A1 (en) 2009-06-25
PL2148880T3 (pl) 2014-10-31
MY154898A (en) 2015-08-28
ECSP099721A (es) 2009-12-28
HK1140767A1 (en) 2010-10-22
TW200848053A (en) 2008-12-16
CL2008001230A1 (es) 2009-05-22
MX2009012075A (es) 2009-11-19
JP2010526814A (ja) 2010-08-05
AR066344A1 (es) 2009-08-12
EA200971051A1 (ru) 2010-06-30
IL201564A (en) 2014-08-31
IL201564A0 (en) 2010-05-31
EP2148880B1 (en) 2014-05-28
KR101088219B1 (ko) 2011-11-30
RS53451B (sr) 2014-12-31
CA2687265A1 (en) 2008-11-20
DOP2009000257A (es) 2010-03-31
AU2008251692A1 (en) 2008-11-20
ES2483726T3 (es) 2014-08-07
TWI423805B (zh) 2014-01-21
EA016445B1 (ru) 2012-05-30
TN2009000446A1 (en) 2011-03-31
JP5503532B2 (ja) 2014-05-28
SI2148880T1 (sl) 2014-07-31
US8093383B2 (en) 2012-01-10
CN101679439B (zh) 2013-09-11
NZ580423A (en) 2012-02-24
CR11106A (es) 2010-04-12
MA31433B1 (fr) 2010-06-01
BRPI0811212A2 (pt) 2014-10-29
US20120071490A1 (en) 2012-03-22
GT200900292A (es) 2011-06-24
EP2148880A1 (en) 2010-02-03
UA99284C2 (ru) 2012-08-10
DK2148880T3 (da) 2014-06-16
AU2008251692B2 (en) 2012-10-11
CN101679439A (zh) 2010-03-24
KR20100005710A (ko) 2010-01-15
PT2148880E (pt) 2014-08-28

Similar Documents

Publication Publication Date Title
NZ594385A (en) Aminopyrimidines useful as kinase inhibitors
MY144655A (en) Pyrimidine urea derivatives as kinase inhibitors
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NZ591712A (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
WO2008057775A3 (en) Heterocyclic amide compounds useful as kinase inhibitors
TW200618800A (en) Heterocyclic compounds
PE20070855A1 (es) Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
MXPA05008878A (es) Derivados de aminotiazol sustituidos con cicloalquilo que contiene n y composiciones farmaceuticas para inhibir la proliferacion celular, y metodos para su uso.
NO20070655L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
WO2006084017A3 (en) Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
MX2009011964A (es) Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico.
PE20130306A1 (es) Morfolinopirimidinas y su uso en terapia
PE20090674A1 (es) Compuestos multiciclicos
TW200738655A (en) Novel bicyclic sulfonamide derivatives
MX2007008784A (es) Derivados de pirazol para la inhibicion de las cdks y gsks.
NZ533310A (en) Benzimidazoles useful as protein kinase inhibitors
NO20070532L (no) Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
MXPA05013349A (es) Derivados de 2-amino-pirimidina como inhibidores de quinasa raf.
PE20090773A1 (es) Derivados de morfolina pirimidina
NZ613219A (en) Heterocyclic containing entities, compositions and methods
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
NO20075987L (no) Bisykliske derviater som p38-kinaseinhibitorer
NZ598144A (en) Kinase inhibitors, prodrug forms thereof and their use in therapy
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed